カテゴリ： 世界, 医療/バイオ, Market Monitor Global

原発性免疫不全薬のグローバル市場展望 2023年-2029年：サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤

■ 英語タイトル：Primary Immunodeficiency Drugs Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8603）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8603
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：73
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[原発性免疫不全薬のグローバル市場展望 2023年-2029年：サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の原発性免疫不全薬市場規模と予測を収録しています。・世界の原発性免疫不全薬市場：売上、2018年-2023年、2024年-2029年
・世界の原発性免疫不全薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の原発性免疫不全薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「サイトカイン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

原発性免疫不全薬のグローバル主要企業は、ADMA Biologics, Inc.、 CSL Behring, LLC、 Octapharma、 Takeda Pharmaceutical Company、 Grifols Biologicals, Inc.、 Baxter、 Kedrion Biopharma、 BPL Inc.、 Pharming Group、 Shire、 Chengdu Rongsheng Pharmaceutical Co., Ltdなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、原発性免疫不全薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の原発性免疫不全薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の原発性免疫不全薬市場：タイプ別市場シェア、2022年
・サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤

世界の原発性免疫不全薬市場：用途別、2018年-2023年、2024年-2029年
世界の原発性免疫不全薬市場：用途別市場シェア、2022年
・病院、専門クリニック、その他

世界の原発性免疫不全薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の原発性免疫不全薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における原発性免疫不全薬のグローバル売上、2018年-2023年
・主要企業における原発性免疫不全薬のグローバル売上シェア、2022年
・主要企業における原発性免疫不全薬のグローバル販売量、2018年-2023年
・主要企業における原発性免疫不全薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
ADMA Biologics, Inc.、 CSL Behring, LLC、 Octapharma、 Takeda Pharmaceutical Company、 Grifols Biologicals, Inc.、 Baxter、 Kedrion Biopharma、 BPL Inc.、 Pharming Group、 Shire、 Chengdu Rongsheng Pharmaceutical Co., Ltd

*************************************************************

・調査・分析レポートの概要
原発性免疫不全薬市場の定義
市場セグメント
世界の原発性免疫不全薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の原発性免疫不全薬市場規模
世界の原発性免疫不全薬市場規模：2022年 VS 2029年
世界の原発性免疫不全薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの原発性免疫不全薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の原発性免疫不全薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤
原発性免疫不全薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、専門クリニック、その他
原発性免疫不全薬の用途別グローバル売上・予測

・地域別市場分析
地域別原発性免疫不全薬市場規模 2022年と2029年
地域別原発性免疫不全薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
ADMA Biologics, Inc.、 CSL Behring, LLC、 Octapharma、 Takeda Pharmaceutical Company、 Grifols Biologicals, Inc.、 Baxter、 Kedrion Biopharma、 BPL Inc.、 Pharming Group、 Shire、 Chengdu Rongsheng Pharmaceutical Co., Ltd
...

Drugs for the treatment of primary immunodeficiency diseases
This report aims to provide a comprehensive presentation of the global market for Primary Immunodeficiency Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Immunodeficiency Drugs. This report contains market size and forecasts of Primary Immunodeficiency Drugs in global, including the following market information:
Global Primary Immunodeficiency Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Primary Immunodeficiency Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Primary Immunodeficiency Drugs companies in 2022 (%)
The global Primary Immunodeficiency Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Cytokines Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Primary Immunodeficiency Drugs include ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Immunodeficiency Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Primary Immunodeficiency Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Primary Immunodeficiency Drugs Market Segment Percentages, by Type, 2022 (%)
Cytokines
Anti Cytokine Antibodies
Signal Molecule Inhibitor
Global Primary Immunodeficiency Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Primary Immunodeficiency Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Specialist Clinic
Othere
Global Primary Immunodeficiency Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Primary Immunodeficiency Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Primary Immunodeficiency Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Primary Immunodeficiency Drugs revenues share in global market, 2022 (%)
Key companies Primary Immunodeficiency Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Primary Immunodeficiency Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
ADMA Biologics, Inc.
CSL Behring, LLC
Octapharma
Takeda Pharmaceutical Company
Grifols Biologicals, Inc.
Baxter
Kedrion Biopharma
BPL Inc.
Pharming Group
Shire
Chengdu Rongsheng Pharmaceutical Co., Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of Primary Immunodeficiency Drugs, market overview.
Chapter 2: Global Primary Immunodeficiency Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Primary Immunodeficiency Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Primary Immunodeficiency Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Primary Immunodeficiency Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Primary Immunodeficiency Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Primary Immunodeficiency Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Primary Immunodeficiency Drugs Overall Market Size
2.1 Global Primary Immunodeficiency Drugs Market Size: 2022 VS 2029
2.2 Global Primary Immunodeficiency Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Primary Immunodeficiency Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Primary Immunodeficiency Drugs Players in Global Market
3.2 Top Global Primary Immunodeficiency Drugs Companies Ranked by Revenue
3.3 Global Primary Immunodeficiency Drugs Revenue by Companies
3.4 Global Primary Immunodeficiency Drugs Sales by Companies
3.5 Global Primary Immunodeficiency Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Primary Immunodeficiency Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Primary Immunodeficiency Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Primary Immunodeficiency Drugs Players in Global Market
3.8.1 List of Global Tier 1 Primary Immunodeficiency Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Primary Immunodeficiency Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Primary Immunodeficiency Drugs Market Size Markets, 2022 & 2029
4.1.2 Cytokines
4.1.3 Anti Cytokine Antibodies
4.1.4 Signal Molecule Inhibitor
4.2 By Type – Global Primary Immunodeficiency Drugs Revenue & Forecasts
4.2.1 By Type – Global Primary Immunodeficiency Drugs Revenue, 2018-2023
4.2.2 By Type – Global Primary Immunodeficiency Drugs Revenue, 2024-2029
4.2.3 By Type – Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Primary Immunodeficiency Drugs Sales & Forecasts
4.3.1 By Type – Global Primary Immunodeficiency Drugs Sales, 2018-2023
4.3.2 By Type – Global Primary Immunodeficiency Drugs Sales, 2024-2029
4.3.3 By Type – Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Primary Immunodeficiency Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Primary Immunodeficiency Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialist Clinic
5.1.4 Othere
5.2 By Application – Global Primary Immunodeficiency Drugs Revenue & Forecasts
5.2.1 By Application – Global Primary Immunodeficiency Drugs Revenue, 2018-2023
5.2.2 By Application – Global Primary Immunodeficiency Drugs Revenue, 2024-2029
5.2.3 By Application – Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Primary Immunodeficiency Drugs Sales & Forecasts
5.3.1 By Application – Global Primary Immunodeficiency Drugs Sales, 2018-2023
5.3.2 By Application – Global Primary Immunodeficiency Drugs Sales, 2024-2029
5.3.3 By Application – Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Primary Immunodeficiency Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Primary Immunodeficiency Drugs Market Size, 2022 & 2029
6.2 By Region – Global Primary Immunodeficiency Drugs Revenue & Forecasts
6.2.1 By Region – Global Primary Immunodeficiency Drugs Revenue, 2018-2023
6.2.2 By Region – Global Primary Immunodeficiency Drugs Revenue, 2024-2029
6.2.3 By Region – Global Primary Immunodeficiency Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Primary Immunodeficiency Drugs Sales & Forecasts
6.3.1 By Region – Global Primary Immunodeficiency Drugs Sales, 2018-2023
6.3.2 By Region – Global Primary Immunodeficiency Drugs Sales, 2024-2029
6.3.3 By Region – Global Primary Immunodeficiency Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Primary Immunodeficiency Drugs Revenue, 2018-2029
6.4.2 By Country – North America Primary Immunodeficiency Drugs Sales, 2018-2029
6.4.3 US Primary Immunodeficiency Drugs Market Size, 2018-2029
6.4.4 Canada Primary Immunodeficiency Drugs Market Size, 2018-2029
6.4.5 Mexico Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Primary Immunodeficiency Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Primary Immunodeficiency Drugs Sales, 2018-2029
6.5.3 Germany Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.4 France Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.5 U.K. Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.6 Italy Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.7 Russia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Primary Immunodeficiency Drugs Market Size, 2018-2029
6.5.9 Benelux Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Primary Immunodeficiency Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Primary Immunodeficiency Drugs Sales, 2018-2029
6.6.3 China Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.4 Japan Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.5 South Korea Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.6.7 India Primary Immunodeficiency Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Primary Immunodeficiency Drugs Revenue, 2018-2029
6.7.2 By Country – South America Primary Immunodeficiency Drugs Sales, 2018-2029
6.7.3 Brazil Primary Immunodeficiency Drugs Market Size, 2018-2029
6.7.4 Argentina Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Primary Immunodeficiency Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Primary Immunodeficiency Drugs Sales, 2018-2029
6.8.3 Turkey Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.4 Israel Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Primary Immunodeficiency Drugs Market Size, 2018-2029
6.8.6 UAE Primary Immunodeficiency Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 ADMA Biologics, Inc.
7.1.1 ADMA Biologics, Inc. Company Summary
7.1.2 ADMA Biologics, Inc. Business Overview
7.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.1.5 ADMA Biologics, Inc. Key News & Latest Developments
7.2 CSL Behring, LLC
7.2.1 CSL Behring, LLC Company Summary
7.2.2 CSL Behring, LLC Business Overview
7.2.3 CSL Behring, LLC Primary Immunodeficiency Drugs Major Product Offerings
7.2.4 CSL Behring, LLC Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.2.5 CSL Behring, LLC Key News & Latest Developments
7.3 Octapharma
7.3.1 Octapharma Company Summary
7.3.2 Octapharma Business Overview
7.3.3 Octapharma Primary Immunodeficiency Drugs Major Product Offerings
7.3.4 Octapharma Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Octapharma Key News & Latest Developments
7.4 Takeda Pharmaceutical Company
7.4.1 Takeda Pharmaceutical Company Company Summary
7.4.2 Takeda Pharmaceutical Company Business Overview
7.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Major Product Offerings
7.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Takeda Pharmaceutical Company Key News & Latest Developments
7.5 Grifols Biologicals, Inc.
7.5.1 Grifols Biologicals, Inc. Company Summary
7.5.2 Grifols Biologicals, Inc. Business Overview
7.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Grifols Biologicals, Inc. Key News & Latest Developments
7.6 Baxter
7.6.1 Baxter Company Summary
7.6.2 Baxter Business Overview
7.6.3 Baxter Primary Immunodeficiency Drugs Major Product Offerings
7.6.4 Baxter Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Baxter Key News & Latest Developments
7.7 Kedrion Biopharma
7.7.1 Kedrion Biopharma Company Summary
7.7.2 Kedrion Biopharma Business Overview
7.7.3 Kedrion Biopharma Primary Immunodeficiency Drugs Major Product Offerings
7.7.4 Kedrion Biopharma Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Kedrion Biopharma Key News & Latest Developments
7.8 BPL Inc.
7.8.1 BPL Inc. Company Summary
7.8.2 BPL Inc. Business Overview
7.8.3 BPL Inc. Primary Immunodeficiency Drugs Major Product Offerings
7.8.4 BPL Inc. Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.8.5 BPL Inc. Key News & Latest Developments
7.9 Pharming Group
7.9.1 Pharming Group Company Summary
7.9.2 Pharming Group Business Overview
7.9.3 Pharming Group Primary Immunodeficiency Drugs Major Product Offerings
7.9.4 Pharming Group Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Pharming Group Key News & Latest Developments
7.10 Shire
7.10.1 Shire Company Summary
7.10.2 Shire Business Overview
7.10.3 Shire Primary Immunodeficiency Drugs Major Product Offerings
7.10.4 Shire Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Shire Key News & Latest Developments
7.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
7.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Company Summary
7.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Business Overview
7.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Major Product Offerings
7.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Key News & Latest Developments
8 Global Primary Immunodeficiency Drugs Production Capacity, Analysis
8.1 Global Primary Immunodeficiency Drugs Production Capacity, 2018-2029
8.2 Primary Immunodeficiency Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Primary Immunodeficiency Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Primary Immunodeficiency Drugs Supply Chain Analysis
10.1 Primary Immunodeficiency Drugs Industry Value Chain
10.2 Primary Immunodeficiency Drugs Upstream Market
10.3 Primary Immunodeficiency Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Primary Immunodeficiency Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 内因性ペプチド物質のグローバル市場展望 2023年-2029年：神経ペプチド、ホルモン、サイトカイン、ペプチドホルモン、生理活性ペプチド
  • 細胞栄養補助食品のグローバル市場展望 2023年-2029年：抗生物質、L-グルタミン&グルタマックスサプリメント、細胞培養緩衝液、成長因子&サイトカイン、ウシ血清アルブミン（BSE）、その他
  • 原発性免疫不全治療薬のグローバル市場展望 2023年-2029年：免疫グロブリン補充療法、幹細胞/骨髄移植、抗生物質療法、遺伝子療法、その他
  • ヒト免疫不全ウイルス抗体検出キットのグローバル市場展望 2023年-2029年：免疫クロマトグラフィー、コロイド金免疫クロマトグラフィー、ラテックス法、その他
  • IgA腎症治療薬のグローバル市場展望 2023年-2029年：第I相、第II相、第III相
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8603 )"原発性免疫不全薬のグローバル市場展望 2023年-2029年：サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤" (英文：Primary Immunodeficiency Drugs Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。